Studies by the scientific founders of Transplant Genomics Inc. (TGI) to be presented at the upcoming American Transplant Congress (ATC) May 2–6 in Philadelphia demonstrate validation of the company’s tests to support management of kidney transplant recipients. The tests are designed to detect early signs of kidney graft injury, differentiate between actionable causes and enable optimization of therapy, with the potential to extend lives and reduce costs of associated healthcare.
“These studies validate the use of our tests in both peripheral blood and biopsies to classify the immune status of kidney graft recipients,” explained Stan Rose, PhD, President & CEO of Transplant Genomics and a kidney transplant recipient himself. “The validation of the first blood-based signature for subclinical acute rejection is an important milestone in our efforts to offer noninvasive serial monitoring of immune status in kidney transplant recipients.”
Validation of Blood and Biopsy Gene Expression-Based Molecular Diagnostics for Subclinical Acute Rejection: Comparing DNA Microarrays Vs. Next-Generation RNA Sequencing will be presented on Sunday, May 3. In this study, Dr. Friedewald, Dr. Kurian and colleagues substantiate RNA sequencing as an alternative data generation platform for analyzing gene expression profiles in blood and tissue from kidney transplant recipients. The data validate that gene expression signatures for subclinical acute rejection, acute rejection and transplant excellence (stable patients) can be detected as robustly with RNA sequencing as with microarrays. Next-generation sequencing has the potential to offer advantages such as reduced cost of analysis and improved throughput for sample processing. Development of kits enabling assay performance on local lab-based sequencing systems could facilitate expansion of test use worldwide.
About Transplant Genomics Inc.
Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results will support clinicians with information to optimize immunosuppression therapy, enhance patient care and improve graft survival. Test services are offered through TGI’s CLIA lab in Pleasanton, CA. www.transplantgenomics.com
Source – BusinessWire
Related Posts
Studies by the scientific founders of Transplant Genomics Inc. (TGI) to be presented at the upcoming American Transplant Congress (ATC) May 2–6 in Philadelphia demonstrate validation of the company’s tests to support management of kidney transplant recipients. The tests are designed to detect early signs of kidney graft injury, differentiate between actionable causes and enable optimization of therapy, with the potential to extend lives and reduce costs of associated healthcare.
“These studies validate the use of our tests in both peripheral blood and biopsies to classify the immune status of kidney graft recipients,” explained Stan Rose, PhD, President & CEO of Transplant Genomics and a kidney transplant recipient himself. “The validation of the first blood-based signature for subclinical acute rejection is an important milestone in our efforts to offer noninvasive serial monitoring of immune status in kidney transplant recipients.”
Validation of Blood and Biopsy Gene Expression-Based Molecular Diagnostics for Subclinical Acute Rejection: Comparing DNA Microarrays Vs. Next-Generation RNA Sequencing will be presented on Sunday, May 3. In this study, Dr. Friedewald, Dr. Kurian and colleagues substantiate RNA sequencing as an alternative data generation platform for analyzing gene expression profiles in blood and tissue from kidney transplant recipients. The data validate that gene expression signatures for subclinical acute rejection, acute rejection and transplant excellence (stable patients) can be detected as robustly with RNA sequencing as with microarrays. Next-generation sequencing has the potential to offer advantages such as reduced cost of analysis and improved throughput for sample processing. Development of kits enabling assay performance on local lab-based sequencing systems could facilitate expansion of test use worldwide.
About Transplant Genomics Inc.
Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results will support clinicians with information to optimize immunosuppression therapy, enhance patient care and improve graft survival. Test services are offered through TGI’s CLIA lab in Pleasanton, CA. www.transplantgenomics.com
Source – BusinessWire
Related Posts
Recent Posts
New method allows scientists to follow gene activity over time in the same cells
Single-cell and single-embryo RNA sequencing
RNA sequencing reveals functional chimeric mRNAs in mammalian immunity
Deep learning improves microRNA target prediction from sequence
New Johns Hopkins Study Identifies Pervasive RT-qPCR Artifact in CRISPR Knockdown Studies and How UltraMarathonRT® Solves It
Atlas of the brain’s striatum could guide researchers to new drug treatments
RNA-Seq Products & Services
Stay Connected